Small molecule agonists of the relaxin 1 receptor

早期翻译处(ETB)与美国国立卫生研究院和校外研究人员保持了130多项积极合作，促进了整个人类疾病范围内的药物发现工作。这些努力导致了数十个高通量筛选和许多药物化学活动，以进一步改进筛选命中，为我们的合作者和一般研究社区提供出版物和各种有前途的小分子探针和线索。此外，资讯科技及广播局亦致力推动多项资讯科技计划，以更有效地利用现有药物及疾病目标资讯，并为市民提供方便取用的资源，进一步推动人类疾病新疗法的发展。 在此期间，合作小组一直致力于使用体外分析和体内模型来表征铅分子。获得了几种分子的体内药代动力学和药效数据。

The Early Translation Branch (ETB) has maintained over 130 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the ETB has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease. During this period, the collaborative team has worked to characterize the lead molecules using in vitro assays and in vivo models. In vivo pharmacokinetics and efficacy data were obtained for several molecules.